Results 111 to 120 of about 18,962 (231)

Positioning Incretin‐Based and Next‐Generation Obesity Management Medications: A Methodological Framework for a Series of Systematic Reviews and Network Meta‐Analyses

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background The obesity pharmacotherapy landscape is evolving rapidly, with several approved incretin‐based therapies and an expanding pipeline of investigational compounds targeting multiple metabolic pathways. Conventional evidence syntheses often struggle to accommodate differences in dose selection, treatment duration and stage of clinical ...
Matteo Monami, Benedetta Ragghianti, Edoardo Mannucci   +2 more
wiley   +1 more source

Efficacy and Safety of Intensifying Once‐Weekly Insulin Icodec Treatment With Once‐Weekly Semaglutide in Adults With Type 2 Diabetes: A Single‐Arm, Open‐Label, Treat‐to‐Target, Phase 3b Trial (ONWARDS 8)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To investigate the efficacy and safety of intensifying once‐weekly insulin icodec (icodec) with once‐weekly semaglutide in adults with type 2 diabetes (T2D). Materials and Methods ONWARDS 8 was a single‐arm, open‐label, treat‐to‐target, Phase 3b trial comprising a 26‐week icodec run‐in period and a 26‐week semaglutide intensification ...
Krzysztof Strojek, Andreas Liebl, Neha Narendra Mumbaikar, Stinne Byrholdt Søgaard, Sara Kehlet Watt, Athena Philis‐Tsimikas   +5 more
wiley   +1 more source

Correction: Protective effects of liraglutide on hypercholesterolemia-associated atherosclerosis involve attenuation of endothelial-monocyte adhesion through down-regulating the LOX-1/NF-κB signaling pathway. [PDF]

Sci Rep
Wu A, Wu Y, Song M, Chen W, Xu K, Wu M, Lin L.   +6 more
europepmc   +1 more source

Tirzepatide for Excess Weight in Adults With Type 1 Diabetes Using MiniMed 780G

Diabetes, Obesity and Metabolism, EarlyView.
Michelantonio De Fano, Rachele Tortoriello, Stefania Rucco, Sofia Corio, Marcello Manco, Edoardo Guerrini, Francesca Porcellati   +6 more
wiley   +1 more source

Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE‐O Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims In the AMPLITUDE O trial, efpeglenatide reduced major cardiovascular events by 27% in 4076 individuals with Type 2 diabetes and established cardiovascular or kidney disease compared to placebo during a median follow‐up of 1.81 years. This exploratory mediation analysis evaluates the degree to which changes in measured clinical variables ...
Daniel Raaschou‐Oddershede, Christine R. Schwarz, Tanya Kovalova, Kelley R. Branch, Stefano Del Prato, Carolyn S. P. Lam, Renato D. Lopes, Richard Pratley, Julio Rosenstock, Naveed Sattar, Hertzel C. Gerstein   +10 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists and rotator cuff disease: a scoping review. [PDF]

BMC Musculoskelet Disord
Duru DO, Zhou AK, Lee DKR, Carroll PJ, Elmaraghy A.   +4 more
europepmc   +1 more source

Tirzepatide Is Associated With Improved Metabolic Outcomes in People With Type 1 Diabetes and Overweight or Obesity: A Retrospective Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the effect of tirzepatide on body weight, glycaemic control, insulin requirements, continuous glucose monitoring (CGM) metrics and cardiorenal parameters in adults with Type 1 diabetes (T1D) and overweight or obesity. Materials and Methods In this retrospective matched cohort study, adults with T1D, BMI ≥ 27 kg/m2, CGM use and
Amanda R. Purcell, Matilda S. G. Longfield, Natassia Rodrigo, Sarah J. Glastras   +3 more
wiley   +1 more source

Efficacy and safety of GLP-1 receptor agonists in patients with metabolic-associated fatty liver diseases: an umbrella review. [PDF]

Front Med (Lausanne)
Wu H, Zhang ZH, Ye T, Chen JN, Tung TH, Zhu JS.   +5 more
europepmc   +1 more source

The Role of Oxidative Stress in Periodontitis

Journal of Periodontal Research, EarlyView.
Oxidative stress is involved in multiple chemical reactions that take place in different intracellular organelles: mitochondria, rough endoplasmic reticulum, peroxisomes, autophagy, and aging, and can be influenced by exogenous factors: nutrition, physical activity, psychological status, environmental conditions, microbiome, and drugs.
Pedro Bullon, Francesca Giampieri, Beatriz Bullon, Maurizio Battino   +3 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists Inhibit the Initiation of Toxic Amyloid-β42 Aggregation. [PDF]

J Am Chem Soc
Fallot LB, Anderson CA, Pinc JR, Stevenson A, Schleck MC, Hawryschuk E, Li OZ, Palchak JC, Toole JR, Kubiak Ii RW, Dear AJ, Michaels TCT, Limbocker R.   +12 more
europepmc   +1 more source